Analiz Rodriguez Data-verified

Affiliation confirmed via AI analysis of OpenAlex, ORCID, and web sources.

Federal Grant PI High Impact

Associate Professor

University of Arkansas

Last publication 2025 Last refreshed 2026-05-22

faculty

Neurosurgery, College of Medicine

arodriguez@uams.edu

26 h-index 181 pubs 7,670 cited

Research Areas

Links

ORCID Lab Website UAMS TRI Profile

OverviewAI-generated summary

Analiz Rodriguez, an Associate Professor in Neurosurgery at the University of Arkansas, studies glioblastoma and other brain tumors. Her research focuses on developing and testing novel therapeutic strategies, including oncolytic virotherapy, CAR-T cell therapies, and precision medicine approaches. She has investigated the efficacy of combining oncolytic DNX-2401 virotherapy with pembrolizumab in recurrent glioblastoma, as detailed in a phase 1/2 trial. Her work also explores the potential of off-the-shelf, CAR T-cells engineered to target IL13Rα2 for glioblastoma treatment.

Dr. Rodriguez utilizes advanced models to understand tumor biology and predict treatment outcomes. This includes functional precision medicine pipelines that combine comparative transcriptomics and tumor organoid modeling to identify bespoke treatment strategies. She also investigates zebrafish cancer avatars as a translational platform for analyzing tumor heterogeneity. Her research has led to publications on the anti-glioblastoma activity of monensin and its analogs in organoid models, as well as the utility of biobanked patient-derived organoids for studying cancer invasion. She has a publication record of 182 papers with 7,562 citations and an h-index of 26. Dr. Rodriguez has served as a Co-PI on an NSF grant totaling $75,000.

Metrics

h-index: 26
Publications: 181
Citations: 7,670

Selected Publications

Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial (2025)

1 citation DOI OpenAlex
Interstitial Thermal Therapy in Mesial Temporal Lobe Epilepsy (2025)

3 citations DOI OpenAlex
Toward standardized brain tumor tissue processing protocols in neuro-oncology: a perspective for gliomas and beyond (2024)

3 citations DOI OpenAlex
Functional prediction of response to therapy prior to therapeutic intervention is associated with improved survival in patients with high-grade glioma (2024)

5 citations DOI OpenAlex
Functional precision medicine assay for recurrent meningioma: a proof of principle. Illustrative case (2024)

1 citation DOI OpenAlex
Immune checkpoint inhibitors as subsequent treatment in older adults with non-small cell lung cancer and synchronous brain metastases (2024)

1 citation DOI OpenAlex
Long-read sequencing for brain tumors (2024)

1 citation DOI OpenAlex
SMARCA4-deficient central nervous system metastases: A case series and systematic review (2024)

2 citations DOI OpenAlex
Laser interstitial thermal therapy for new and recurrent meningioma: a prospective and retrospective case series (2024)

7 citations DOI OpenAlex
Synthesis and Anti‐Melanoma Activity of Acryloyl Pyridinone Analogues (2023)

1 citation DOI OpenAlex
CTIM-19. ONCOLYTIC DNX-2401 VIROTHERAPY PLUS PEMBROLIZUMAB IN RECURRENT GLIOBLASTOMA: A PHASE 1/2 TRIAL (2023)

5 citations DOI OpenAlex
1211 Defining the role of PCK2 in T cell metabolic plasticity in Glioblastoma (2023)

1 citation DOI OpenAlex
Bifunctional Inhibitor Reveals NEK2 as a Therapeutic Target and Regulator of Oncogenic Pathways in Lymphoma (2023)

13 citations DOI OpenAlex
Real-World Survival of First-Line Immune Checkpoint Inhibitor Treatment Versus Chemotherapy in Older Patients With Non–Small-Cell Lung Cancer and Synchronous Brain Metastases (2023)

12 citations DOI OpenAlex
Using the Chick Embryo Brain as a Model for <em>In Vivo</em> and <em>Ex Vivo</em> Analyses of Human Glioblastoma Cell Behavior (2023)

2 citations DOI OpenAlex

View all publications on OpenAlex →

Federal Grants 1 $75,000 total

NSF Co-PI Oct 2024 - Mar 2025

CIVIC-PG Track B: Mobility and Aging in Collaboration (MAGIC): A Transportation Platform for Older Adults

S&CC: Smart & Connected Commun, Special Initiatives $75,000

Grants & Funding

A Phase IlI Clinical Trial Evaluating DCVax-L, Autologous Dendritis Cells Pulsed Northwest Biotherapeutics, Inc. Principal Investigator
Development of immunocompetent melanoma brain metastases organoids NIH/Nat. Cancer Institute Principal Investigator
A Phase IlI Clinical Trial Evaluating DCVax-L, Autologous Dendritis Cells Pulsed Northwest Biotherapeutics, Inc. Principal Investigator
Development of immunocompetent melanoma brain metastases organoids NIH/Nat. Cancer Institute Principal Investigator
No FP attached UAMS Internal Research Awards Principal Investigator
Photobiomodulation to Ameliorate Neuronal Degeneration and Cognitive Decline after Mixed Field Irradiation - Continuation National Aeronautics & Space Administration Co-Investigator
Center for Studies of Host Response to Cancer Therapy NIH Co-Investigator
Novel Platform linking cancer-specific glycosylation with cell signaling outcomes NIH Co-Investigator